恩替卡韦联合复方鳖甲软肝片治疗慢性乙型肝炎早期肝硬化二年疗效观察

Two years clinical observation on the efficacy of entecavir combined Fufang Biejia Ruangan Pian in the treatment of early cirrhosis induced by chronic hepatitis B

目的观察恩替卡韦(ETV)联合复方鳖甲软肝片治疗慢性乙型肝炎(CHB)致早期肝硬化的疗效。方法 74例CHB早期肝硬化患者随机分为治疗组(ETV+复方鳖甲软肝片)和对照组(单用ETV)各37例,治疗24个月。观察两组肝功能,乙型肝炎病毒血清标记物(HBVM),HBV-DNA定量及肝纤维化指标的变化。结果疗程结束后肝功能改善及HBV-DNA定量下降方面,两组无显著性差异(P>0.05);在HBe Ag血清学转换及肝纤维化各项指标改善,两组比较有显著性差异(P<0.05);治疗组总有效率(达67.56%)明显高于对照组的35.13%(P<0.05)。结论 ETV联合复方鳖甲软肝片治疗CHB早期肝硬化安全性和耐受性良好。联合用药优于单一用药,延缓肝硬化进程,值得临床应用。

Objective To observe the curative effect of entecavir （ETV） joint Fufang Biejia Ruangan Pian in the treatment of early liver cirrhosis induced by chronic hepatitis B. Methods 74 patients with early liver cirrhosis induced by CHB were randomly divided into treatment group （TEV combined with Fufang Biejia Ruangan Pian） and the control group （ ETV alone）, 37 cases in each group, the treatment lasted for 24 months. Liver function, the hepatitis b virus serum markers （ HBVM）, HBV - DNA quantitative and liver fibrosis index changes of the two groups were observed. Results After the treatment, the improvement of liver function and the decline of HBV - DNA quantitative of two groups have no significant difference （ P 〉 O. 05 ）. The differences of HBeAg seroconversion and liver fibrosis indicators improvement were statistically significant （ P 〈0. 05 ）. Total effective rate of treatment group was 68% which was significantly higher than36% of the control group （ P 〈 0. 05 ）. Conclusions ETV joint Fufang Biejia Ruangan Pian present well safety and well tolerance in the treatment of early cirrhosis of the liver induced by CHB. In delaying the process of cirrhosis of the liver, combination is superior to the single drug, worthy of clinical application.